Edward Tenthoff
Stock Analyst at Piper Sandler
(3.03)
# 2,640
Out of 5,044 analysts
179
Total ratings
43.02%
Success rate
0.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $5.95 | +101.68% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $3.86 | +210.88% | 2 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $304 → $449 | $442.40 | +1.49% | 14 | Aug 1, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $11.97 | +25.31% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $2.44 | +104.92% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $61.80 | +69.90% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $1.01 | +98.02% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.36 | +414.71% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $9.58 | -6.05% | 4 | May 29, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $9.93 | +40.99% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.58 | +244.83% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $23.66 | +102.92% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $16.24 | +47.78% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $31.70 | +146.06% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $14.51 | +106.75% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $40.45 | +11.25% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $24.64 | +180.03% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $10.51 | +518.46% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $6.35 | +451.18% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.53 | +1,207.19% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.43 | +109.79% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.70 | +328.51% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $12.53 | +27.69% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.34 | +349.44% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.86 | +168.82% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $59.99 | -6.65% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $30.98 | +700.52% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.88 | +2,219.59% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $17.49 | +929.16% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.75 | +147.89% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $8.31 | +345.25% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.43 | +45,698,145.61% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $785.46 | -54.93% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.77 | +7,527.12% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $420.57 | -23.20% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $39.39 | -8.61% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $0.97 | +2,477.32% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.34 | +11,094.03% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.57 | +241,835.48% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $653.00 | - | 11 | Feb 13, 2017 |
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.95
Upside: +101.68%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $3.86
Upside: +210.88%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $304 → $449
Current: $442.40
Upside: +1.49%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $11.97
Upside: +25.31%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $2.44
Upside: +104.92%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $61.80
Upside: +69.90%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $1.01
Upside: +98.02%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.36
Upside: +414.71%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $9.58
Upside: -6.05%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $9.93
Upside: +40.99%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.58
Upside: +244.83%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $23.66
Upside: +102.92%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $16.24
Upside: +47.78%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $31.70
Upside: +146.06%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $14.51
Upside: +106.75%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $40.45
Upside: +11.25%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $24.64
Upside: +180.03%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $10.51
Upside: +518.46%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $6.35
Upside: +451.18%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.53
Upside: +1,207.19%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.43
Upside: +109.79%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.70
Upside: +328.51%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $12.53
Upside: +27.69%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.34
Upside: +349.44%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.86
Upside: +168.82%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $59.99
Upside: -6.65%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $30.98
Upside: +700.52%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.88
Upside: +2,219.59%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $17.49
Upside: +929.16%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.75
Upside: +147.89%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $8.31
Upside: +345.25%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.43
Upside: +45,698,145.61%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $785.46
Upside: -54.93%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.77
Upside: +7,527.12%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $420.57
Upside: -23.20%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $39.39
Upside: -8.61%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $0.97
Upside: +2,477.32%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.34
Upside: +11,094.03%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.57
Upside: +241,835.48%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $653.00
Upside: -